What is Cellectis S.A. (CMVLF) stock price today?

Cellectis S.A. (CMVLF) is currently trading at $3.47, up 12.66% today.

What is CMVLF P/E ratio?

Cellectis S.A.'s P/E ratio is -4.24. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CMVLF return on equity (ROE)?

Cellectis S.A.'s return on equity (ROE) is -80.61%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Cellectis S.A.'s market cap?

Cellectis S.A. has a market capitalization of $251.93M.

OTC · Biotechnology

Cellectis S.A. (CMVLF) Stock

$3.47 +12.66% OTC: CMVLF Healthcare

Cellectis S.A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies.

Valuation

Metric	Value
Price	$3.47
Market Cap	$251.93M
P/E Ratio	-4.24
P/B Ratio	4.80
P/S Ratio	3.04
EPS (TTM)	$-0.70
52-Week High	$5.04
52-Week Low	$1.25
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-80.61%
ROA	-23.26%
ROCE	-30.50%
Gross Margin	78.86%
Operating Margin	-69.23%
Net Margin	-98.69%
Debt/Equity	1.38
Current Ratio	1.52

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$74.0M	$19.0M	$1.0M	$42.0M	$76.0M
Operating Profit	$-85.0M	$-90.0M	$-109.0M	$-60.0M	$-42.0M
Net Profit	$-81.0M	$-106.0M	$-103.0M	$-37.0M	$-70.0M
EPS	$-1.81	$-2.33	$-1.77	$-0.41	$-0.70
Op Margin	-115.5%	-467.7%	-14418.2%	-143.5%	-55.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$382.0M	$261.0M	$334.0M	$384.0M	$325.0M
Total Liabilities	$146.0M	$135.0M	$250.0M	$253.0M	$249.0M
Cash	$186.0M	$98.0M	$137.0M	$143.0M	$64.0M
Borrowings	$101.0M	$76.0M	$85.0M	$91.0M	$120.0M

Latest News

Vallourec to supply pipes for Atapu 2 offshore project in Brazil Offshore Technology · Jul 23, 2026 Micron and Sandisk Are Surging: Can the Rally Last Through 2027? Motley Fool · Jul 23, 2026 Net Asset Value(s) Business Wire · Jul 23, 2026 Retiring With Lots of Savings? 2 Social Security Claiming Strategies to Look At. Motley Fool · Jul 23, 2026 Arista Networks Insider Sold Shares Worth $7,388,872, According to a Recent SEC Filing MT Newswires · Jul 23, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-105.0M	$-87.0M	$-25.0M	$23.0M	$-42.0M
Investing Cash Flow	$-12.0M	$-5.0M	$-30.0M	$-107.0M	$-33.0M
Financing Cash Flow	$14.0M	$8.0M	$-10.0M	$-1.0M	$-1.0M
Net Cash Flow	$-56.0M	$-92.0M	$43.0M	$7.0M	$-80.0M
Free Cash Flow	$-124.0M	$-90.0M	$-26.0M	$19.0M	$-44.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.05
EV / EBITDA	-5.66
FCF Yield	-19.32%
Quick Ratio	1.52
Interest Coverage	-5.58
Return 1Y	34.50%
Return 3Y	76.14%
Return 5Y	-74.20%

Ownership

Insiders Held48.01%

Institutions Held10.07%

Institutions Float Held19.36%

Institutional Holder	Shares	Report Date
SEI Inst. INVESTMENTS TRT-SIIT Screened World Eqy. Ex-US Fd.	69	2025-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLVLFClinuvel Pharmaceuticals Limited	$6.37	+0.00%	13.94	$321.12M	0.47%
CYDYCytoDyn Inc.	$0.19	+0.00%	-5.94	$260.25M	0.00%
FGHQFFrontage Holdings Corporation	$0.15	+11.11%	44.83	$304.16M	0.00%
HLOSFHealios K.K.	$1.80	+0.00%	-9.76	$243.00M	0.00%
HNSBFHansa Biopharma AB	$2.90	+0.00%	-4.72	$289.23M	0.00%

About Cellectis S.A.

Cellectis S.A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies. Their core technology involves engineering T-cells with gene editing to express chimeric antigen receptors (CARs), enabling these modified cells to precisely target and destroy cancer cells. The company's operations are structured into two principal divisions: Therapeutics and Plants. Its robust development pipeline includes several crucial product candidates. Notable among these is UCART19, an allogeneic T-cell treatment designed for CD19-expressing blood cancers like acute lymphoblastic leukemia. They are also progressing ALLO-501 and ALLO-501A, aimed at tackling relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. Further candidates encompass ALLO-316 for renal cell carcinoma, UCART123 for acute myeloid leukemia, and UCART22 for B-cell acute lymphoblastic leukemia. Additionally, the company is advancing UCARTCS1 and ALLO-715 in its efforts against multiple myeloma. Cellectis has forged significant strategic partnerships with organizations such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. Furthermore, it maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was established in 1999 and its headquarters are located in Paris, France.

Cellectis S.A. is headquartered in FR.

Cellectis S.A. (CMVLF) stock trades at $3.47 with a market capitalization of $251.93M. The stock is valued at a price-to-earnings (P/E) ratio of -4.24, price-to-book of 4.80, price-to-sales of 3.04. Over the past 52 weeks the stock has ranged between $1.25 and $5.04, and currently trades 31.2% below its 52-week high.

On profitability, Cellectis S.A. generates a return on equity (ROE) of -80.61%, return on capital employed of -30.50%, an operating margin of -69.23%, a net profit margin of -98.69%.

Official website: www.cellectis.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides